1
|
Cui T, Qi Z, Wang M, Zhang X, Wen W, Gao S, Zhai J, Guo C, Zhang N, Zhang X, Guan Y, Retnakaran R, Hao W, Zhai D, Zhang R, Zhao Y, Wen SW. Thyroid allostasis in drug-free affective disorder patients. Psychoneuroendocrinology 2024; 162:106962. [PMID: 38277991 DOI: 10.1016/j.psyneuen.2024.106962] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/25/2023] [Revised: 12/28/2023] [Accepted: 01/10/2024] [Indexed: 01/28/2024]
Abstract
AIM To assess the thyroid allostasis in drug-free patients with affective disorder. METHODS Patients with major depressive disorder or bipolar disorder as drug-free, defined as those without psychiatric drugs exposure for at least 4 months before admission, from a tertiary hospital were recruited in this cross-sectional study. The primary outcomes were "structure parameters of thyroid homeostasis", which include "thyroid's secretory capacity" (SPINA-GT), "sum step-up activity of deiodinases" (SPINA-GD), the ratio of total to free thyroxine and "thyroid homeostasis central set point" (TSH index and "thyroid feedback quantile-based index" [TFQI]), calculated by TSH and thyroid hormones measured at admission. A healthy population and non-affective psychiatric disorder (schizophrenia) from the same catchment area were recruited as two comparison groups. RESULTS A total of 1263 cases of major depressive disorder, 1619 cases of bipolar disorder, 1186 cases of schizophrenia, and 162 healthy controls were included in the study. Compared to healthy control, GD and ratio of total to free thyroxine were lower in affective disorders. Bipolar with mania episode had higher GT than bipolar with depressive episode and major depressive disorder (median level at 3.70 vs. 3.04 and 3.03, respectively). Compared with healthy control, schizophrenia had higher TSH index and TFQI, but no increase in these parameters in major depressive disorder and bipolar disorder. CONCLUSION Affective disorders have a unique profile of thyroid allostasis with impaired step-up deiodinase activity and reduced serum protein binding of thyroid hormones, but no change in thyroid homeostasis central set point. Mania episode may be associated with higher thyroid secretory capacity.
Collapse
Affiliation(s)
- Taizhen Cui
- The Second Affiliated Hospital of Xinxiang Medical University (Henan Mental Hospital), Henan Collaborative Innovation Center of Prevention and treatment of mental disorder, Xinxiang 453002, China; School of Pharmacy, Xinxiang Medical University, Xinxiang 453003, China; Xinxiang Key Laboratory of Clinical Psychopharmacology, Xinxiang Medical University, Xinxiang 453003, China
| | - Zhenyong Qi
- School of Public Health, Xinxiang Medical University, Xinxiang 453003, China
| | - Mengwei Wang
- School of Pharmacy, Xinxiang Medical University, Xinxiang 453003, China
| | - Xuejie Zhang
- School of Public Health, Xinxiang Medical University, Xinxiang 453003, China
| | - Wendy Wen
- McLaughlin Centre for Population Health Risk Assessment, University of Ottawa Faculty of Medicine, Ottawa, Ontario, Canada
| | - Songyin Gao
- Zhumadian Second People's Hospital, Zhumadian Mental Health Center, Zhumadian 463000, China
| | - Jianchun Zhai
- The Fourth Affiliated Hospital of Xinxiang Medical University (Xinxiang Central Hospital), Xinxiang 453000, China
| | - Chao Guo
- School of Pharmacy, Xinxiang Medical University, Xinxiang 453003, China
| | - Nan Zhang
- School of Pharmacy, Xinxiang Medical University, Xinxiang 453003, China
| | - Xue Zhang
- Division of Endocrinology and Metabolism, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang 453003, China
| | - Yiyun Guan
- School of Mechanical Engineering,Henan Institute of Technology, Xinxiang 453000, China
| | - Ravi Retnakaran
- Division of Endocrinology and Metabolism, University of Toronto, Toronto, Canada; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada
| | - Wei Hao
- The Second Affiliated Hospital of Xinxiang Medical University (Henan Mental Hospital), Henan Collaborative Innovation Center of Prevention and treatment of mental disorder, Xinxiang 453002, China
| | - Desheng Zhai
- The Second Affiliated Hospital of Xinxiang Medical University (Henan Mental Hospital), Henan Collaborative Innovation Center of Prevention and treatment of mental disorder, Xinxiang 453002, China; School of Public Health, Xinxiang Medical University, Xinxiang 453003, China; Henan International Joint Laboratory of non-Invasive Neuro-modulation, Xinxiang Medical University, Xinxiang 453003, China.
| | - Ruiling Zhang
- The Second Affiliated Hospital of Xinxiang Medical University (Henan Mental Hospital), Henan Collaborative Innovation Center of Prevention and treatment of mental disorder, Xinxiang 453002, China.
| | - Ying Zhao
- The Second Affiliated Hospital of Xinxiang Medical University (Henan Mental Hospital), Henan Collaborative Innovation Center of Prevention and treatment of mental disorder, Xinxiang 453002, China; School of Pharmacy, Xinxiang Medical University, Xinxiang 453003, China; Xinxiang Key Laboratory of Clinical Psychopharmacology, Xinxiang Medical University, Xinxiang 453003, China.
| | - Shi Wu Wen
- OMNI Research Group, Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, Canada; School of Epidemiology and Public Health, University of Ottawa Faculty of Medicine, Ottawa, Canada; Department of Obstetrics and Gynecology, University of Ottawa Faculty of Medicine, Ottawa, Canada
| |
Collapse
|
2
|
Zhai D, Bing J, Shan X, Luo H, Wen W, Gao S, Niu K, Cui T, Li H, Retnakaran R, Hao W, Zhang R, Zhao Y, Wen SW. Higher central set point of thyroid homeostasis in drug-naïve patients affected by first episode schizophrenia. Schizophr Res 2022; 250:62-66. [PMID: 36368279 DOI: 10.1016/j.schres.2022.10.022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/09/2022] [Revised: 09/15/2022] [Accepted: 10/30/2022] [Indexed: 11/09/2022]
Abstract
AIM To assess central set point of thyroid homeostasis in drug-naïve patients affected by first episode schizophrenia. METHODS This cross-sectional study was conducted in Xinxiang city, Henan, China. Patients were drug-naïve patients affected by first episode schizophrenia, aged 14-50 years old and admitted to the "Second Affiliated Hospital of Xinxiang Medical University" from January 2018 to December 2018. Controls were healthy individuals who underwent annual health from Xinxiang city, a community population of the same age and time period. The parameters of "central set point of thyroid homeostasis" were measured by "thyroid-stimulating hormone (TSH) index" and "thyroid feedback quantile-based index". The parameters were compared between schizophrenia patients and controls. Linear regression models adjusted by age and sex were used to assess the association of schizophrenia with the parameters. RESULTS A total of 235 patients and 121 controls were included in this study. Patients affected by schizophrenia had significantly higher prevalence of hyperthyroxinemia and levels of free T4, "TSH index", and "thyroid feedback quantile-based index" than controls. After adjusting age and sex, schizophrenia was independently associated with the higher level of "TSH index" (adjusted β 0.33, 95 % confidence interval 0.17, 0.49) and "thyroid feedback quantile-based index" (adjusted β 0.21, 95 % confidence interval 0.12, 0.30). The results with age and sex matched patients and controls were similar to those observed in the overall study population. CONCLUSION Higher central set point may be the underlying mechanism of thyroid allostatic load in drug-naïve patients affected first episode schizophrenia.
Collapse
Affiliation(s)
- Desheng Zhai
- The Second Affiliated Hospital of Xinxiang Medical University (Henan Mental Hospital), Xinxiang 453002, China; School of Public Health, Xinxiang Medical University, Xinxiang 453003, China.
| | - Jialuo Bing
- School of Public Health, Xinxiang Medical University, Xinxiang 453003, China
| | - Xuchang Shan
- School of Public Health, Xinxiang Medical University, Xinxiang 453003, China
| | - Hu Luo
- The Second Affiliated Hospital of Xinxiang Medical University (Henan Mental Hospital), Xinxiang 453002, China
| | - Wendy Wen
- McLaughlin Centre for Population Health Risk Assessment, University of Ottawa Faculty of Medicine, Ottawa, Ontario, Canada
| | - Songyin Gao
- Zhumadian Mental Health Center, Zhumadian 463000, China
| | - Kaijun Niu
- Nutritional Epidemiology Institute and School of Public Health, Tianjin Medical University, Tianjin, China
| | - Taizhen Cui
- School of Pharmacy, Xinxiang Medical University, Xinxiang 453003, China; Xinxiang Key Laboratory of Clinical Psychopharmacology, Xinxiang Medical University, Xinxiang 453003, China
| | - Hongbin Li
- School of Public Health, Xinxiang Medical University, Xinxiang 453003, China
| | - Ravi Retnakaran
- Division of Endocrinology and Metabolism, University of Toronto, Toronto, Canada; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada
| | - Wei Hao
- The Second Affiliated Hospital of Xinxiang Medical University (Henan Mental Hospital), Xinxiang 453002, China
| | - Ruiling Zhang
- The Second Affiliated Hospital of Xinxiang Medical University (Henan Mental Hospital), Xinxiang 453002, China.
| | - Ying Zhao
- School of Pharmacy, Xinxiang Medical University, Xinxiang 453003, China; Xinxiang Key Laboratory of Clinical Psychopharmacology, Xinxiang Medical University, Xinxiang 453003, China; Henan International Joint Laboratory of non-Invasive Neuro-modulation, Xinxiang Medical University, Xinxiang 453003, China.
| | - Shi Wu Wen
- OMNI Research Group, Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, Canada; School of Epidemiology and Public Health, University of Ottawa Faculty of Medicine, Ottawa, Canada; Department of Obstetrics and Gynecology, University of Ottawa Faculty of Medicine, Ottawa, Canada
| |
Collapse
|
3
|
Zhai D, Chen J, Guo B, Retnakaran R, Gao S, Zhang X, Hao W, Zhang R, Zhao Y, Wen SW. Oxcarbazepine was associated with risks of newly developed hypothyroxinaemia and impaired central set point of thyroid homeostasis in schizophrenia patients. Br J Clin Pharmacol 2021; 88:2297-2305. [PMID: 34855997 DOI: 10.1111/bcp.15163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2021] [Revised: 10/17/2021] [Accepted: 11/15/2021] [Indexed: 11/27/2022] Open
Abstract
AIMS Hypothyroxinaemia might be easily ignored, because attention is typically paid to individuals with elevated thyroid stimulating hormone (TSH). In this study, we aimed to evaluate the association of oxcarbazepine use as adjuvant for treatment of schizophrenia with hypothyroxinaemia and central set point of thyroid homeostasis. METHODS This retrospective cohort study was conducted in the Second Affiliated Hospital of Xinxiang Medical University. Inpatients with a diagnosis of schizophrenia admitted between January 2016 and October 2019 with normal thyroid function at admission were included. Oxcarbazepine use was the exposure measure. Newly developed hypothyroxinaemia was the primary outcome measure and parameters of thyroid homeostasis central set point as measured by TSH index and thyroid feedback quantile-based index (TFQI) were the secondary outcome measures. RESULTS In total, 1207 eligible patients were included. The occurrence of hypothyroxinaemia in patients who received oxcarbazepine was higher (35/107, 32.7%) than in those patients who did not (152/1099, 13.8%), with adjusted relative risk of 2.24 and 95% confidence interval of 1.57 and 3.17. Oxcarbazepine use was associated with greater reduction in TSH index (adjusted β -0.33 and 95% confidence interval -0.48, -0.19) and TFQI (adjusted β -0.24 and 95% confidence interval -0.31, -0.16). CONCLUSION Oxcarbazepine use was independently associated with increased risk of developing hypothyroxinaemia, and greater reduction in TSH index and TFQI, suggesting that impaired central set point of thyroid homeostasis might be involved in the mechanism of oxcarbazepine-induced hypothyroxinaemia.
Collapse
Affiliation(s)
- Desheng Zhai
- Xinxiang Medical University, The Second Affiliated Hospital, Xinxiang, China.,School of Public Health, Xinxiang Medical University, Xinxiang, China
| | - Jinni Chen
- School of Public Health, Xinxiang Medical University, Xinxiang, China
| | - Baoqiang Guo
- School of Public Health, Xinxiang Medical University, Xinxiang, China
| | - Ravi Retnakaran
- Division of Endocrinology and Metabolism, University of Toronto, Toronto, Canada.,Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada
| | - Songyin Gao
- Zhumadian Mental Health Center, Zhumadian, China
| | - Xiangyang Zhang
- Xinxiang Medical University, The Second Affiliated Hospital, Xinxiang, China
| | - Wei Hao
- Xinxiang Medical University, The Second Affiliated Hospital, Xinxiang, China
| | - Ruiling Zhang
- Xinxiang Medical University, The Second Affiliated Hospital, Xinxiang, China
| | - Ying Zhao
- School of Pharmacy, Xinxiang Medical University, Xinxiang, China.,Xinxiang Key Laboratory of Clinical psychopharmacology, Xinxiang Medical University, Xinxiang, China.,Henan International Joint Laboratory of Non-Invasive Neuro-modulation, Xinxiang Medical University, Xinxiang, China
| | - Shi Wu Wen
- OMNI Research Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada.,School of Epidemiology and Public Health, University of Ottawa Faculty of Medicine, Ottawa, Canada.,Department of Obstetrics, Gynecology, and Newborn Care, University of Ottawa Faculty of Medicine, Ottawa, Canada
| |
Collapse
|